EUVIMEDEUVIMED entdecken
Systematische Übersicht

Efficacy and safety of asfotase alfa in patients with hypophosphatasia: A systematic review

Amirhossein Shirinezhad, Sina Esmaeili, Alireza Azarboo, Yasaman Tavakoli, Amir Human Hoveidaei, Negar Zareshahi, Amirhossein Ghaseminejad-Raeini

Bone · 2024

DOI: 10.1016/j.bone.2024.117219 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Bone, 2024. Verfasst von Amirhossein Shirinezhad und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Hypophosphatasia, Alkaline Phosphatase, Immunoglobulin G, Recombinant Fusion Proteins. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Hypophosphatasia (HPP) is a rare genetic disorder characterized by defective bone mineralization, leading to skeletal abnormalities and systemic complications. Asfotase alfa, a recombinant human tissue-nonspecific alkaline phosphatase (TNSALP) enzyme replacement therapy, has emerged as a promising treatment for HPP. However, a comprehensive evaluation of its efficacy and safety is warranted to guide clinical practice effectively. METHODS: The study followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered in Prospective Register of Systematic Reviews (PROSPERO). A search strategy across databases found studies on asfotase alfa for HPP. Two researchers independently extracted and assessed data. This systematic review examined how the drug impacted clinical outcomes such as survival rates, musculoskeletal symptoms, respiratory function, growth measurements, dental health, quality of life, and laboratory results. RESULTS: This systematic review included 15 articles with a total of 455 HPP patients. Asfotase alfa was predominantly administered at a dose of 6 mg per kg per week among the reviewed studies. Notable findings included enhanced survival rates, relief from musculoskeletal pain, improvements in respiratory outcomes, growth parameters, dental health, and quality of life. Changes in laboratory variables indicated positive responses to treatment, including changes such as increase in alkaline phosphatase (ALP), decline in pyridoxal 5'-phosphate (PLP) and inorganic pyrophosphate (PPi) levels. CONCLUSION: Asfotase alfa demonstrates efficacy in improving clinical outcomes and safety in patients with HPP. Its therapeutic benefits extend across various domains. However, Larger, age-stratified comparative studies are needed to further investigate the drug's effects in HPP patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypophosphatasiaAlkaline PhosphataseImmunoglobulin GRecombinant Fusion ProteinsHumansTreatment OutcomeEnzyme Replacement TherapyQuality of Life

Stichwörter der Autor:innen

Asfotase alfaBoneHypophosphatasiaSystematic reviewTreatment

Substanzen

asfotase alfaAlkaline PhosphataseImmunoglobulin GRecombinant Fusion Proteins

Autor:innen und Institutionen

  • School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
  • Sina University Hospital, Tehran University of Medical Sciences, Tehran, Iran.
  • School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: ar-Azarboo@student.tums.ac.ir.
  • Student Research Committee, Department of Medicine, Mazandaran University of Medical Sciences, Mazandaran, Iran.
  • International Center for Limb Lengthening, Rubin Institute for Advanced Orthopedics, Sinai Hospital of Baltimore, Baltimore, Maryland, USA.
  • School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: ahgnr1999@gmail.com.

Zitieren

APA

Shirinezhad, A., Esmaeili, S., Azarboo, A., Tavakoli, Y., Hoveidaei, A. H., Zareshahi, N., & Ghaseminejad-Raeini, A. (2024). Efficacy and safety of asfotase alfa in patients with hypophosphatasia: A systematic review. Bone. https://doi.org/10.1016/j.bone.2024.117219

Vancouver

Shirinezhad A, Esmaeili S, Azarboo A, Tavakoli Y, Hoveidaei AH, Zareshahi N, et al. Efficacy and safety of asfotase alfa in patients with hypophosphatasia: A systematic review. Bone. 2024. doi:10.1016/j.bone.2024.117219

BibTeX
@article{Shirinezhad2024,
  author = {Shirinezhad, Amirhossein and Esmaeili, Sina and Azarboo, Alireza and Tavakoli, Yasaman and Hoveidaei, Amir Human and Zareshahi, Negar and Ghaseminejad-Raeini, Amirhossein},
  title = {Efficacy and safety of asfotase alfa in patients with hypophosphatasia: A systematic review},
  journal = {Bone},
  year = {2024},
  doi = {10.1016/j.bone.2024.117219}
}
Kostenlos starten →